NEWS: The Australian - 29/07/09 'Real-time alert tool should be compulsory'

[rolls]

P_D; What is the difference between octapomine, synephrine and phenylephrine?

 

[MrIbis]

yeah, stop the small time addicts buying codeine, and i bet the amount of users of street opiates jumps dramatically.

 

[MrIbis]

Ephedrine and psudo are the same thing, psudo is just synthetic. Speed and ice are the same drug but ice is more pure and speed is cut a fair bit to make it easyer to snort.

Will there eventually come a time when people stop posting retarded comments like this? seriously. That information is totally wrong, as doctor war and p_d pointed out.

speed and ice are the same drug, but the reality is that, and i've said it before - one sample of 'speed' could be far more pure methamphetamine than anohter sample of 'ice'. And in recent times, this has definately been the case - unless you think smoking MSM is cool.

Also, i don't see 'speed' snorted very often anymore.

 

[leigh12]

^^i fukn loovvvvvveeeeeeee railing my speed . more so than smoking

 

[static_mind]

Ice is generally considered stronger then speed. Not always the case. And heaps of people snort speed!

 

[fortehlulz]

Thankfully, the Victorian Pharmacy Guild isn't the quickest thing around.

 

[phase_dancer]

P_D; What is the difference between octapomine, synephrine and phenylephrine?

Synephrine is the N-methyl homologue of octopamine. Both have a OH substitution on the 4th position (para) of the aromatic ring.

Phenephrine is similar in structure to synephrine only with the OH substitute on the 3rd position (meta). It works primarily on alpha adrenergic receptors, whereas the 4th position substitution of octopamine and synephrine are thought to probably also work on some Beta receptors.

Activity of all three is probably mostly on the peripheral nervous system rather than the CNS.

Check PubChem or wiki for more info

 

[belarki]

http://www.pharmacynews.com.au/article/tighter-restrictions-for-codeine/493242.aspx

Tighter restrictions for codeine
5 August 2009 | by Simone Roberts

Most over-the-counter (OTC) products containing codeine will be upscheduled to Pharmacist-Only medicines next year.

The National Drugs and Poisons Schedule Committee (NDPSC) today revealed its decision to move OTC combination analgesics containing codeine (CACC) from Schedule 2 to Schedule 3 in a bid to address concerns of misuse and abuse of the products.

The committee also decided to limit the duration of treatment for the drugs to no more than five days and to limit the maximum daily dose of codeine in the products to no more than 100mg.

Codeine combinations for cough and colds escaped the changes, with the committee stating there was no evidence indicating a problem of misuse of these products.

In its record of reasons, the NDPSC said while upscheduling all codeine combinations to S3 would not stop the addiction problem, it would help mitigate it.

"In particular it would ensure pharmacist involvement and provide an opportunity to pick up signals of misuse or abuse," one committee member said.

"Several comments from addiction specialists indicated that such interactions were a significant trigger for addicts to eventually seek help."

The Pharmacy Guild of Australia failed in its attempts to halt the changes by recommending the use of real time monitoring system NotifyRx, similar to Project STOP, to assist in managing the risks and potential for abuse associated with the drugs.

The committee said the proposed system was impractical for several reasons including the cost of installation and maintenance, possible delays in implementing the system and privacy concerns and suggested the Guild has a "vested interest" in its use.

"Members agreed that, at this time, the consideration should remain focused on limiting access, rather than in introducing some sort of real-time monitoring system," the record said.

"Face to face counselling from a pharmacist should be viewed as the primary tool for mitigating the risk of abuse."

The changes are due to be implemented on 1 May, 2010.